Modalis Therapeutics Corporation (JP:4883)
:4883
Want to see JP:4883 full AI Analyst Report?
Top Page
Modalis Therapeutics Corporation
(4883)
Select Model
Select Model
Rating:42Neutral
Price Target:
¥33.00
▼(-41.07% Downside)
Action:Reiterated
Date:05/29/26
The score is primarily constrained by weak financial performance (minimal revenue, recurring losses, and sustained cash burn with equity erosion). Technicals also weigh on the score due to a clear downtrend and negative momentum, despite oversold readings. Valuation provides limited offset because losses make the negative P/E less informative and no dividend yield is available.
Positive Factors
Low financial leverage (debt-free recent years)
Reported zero debt in 2024–2025 reduces fixed financing obligations and lowers near-term bankruptcy risk for a development-stage biotech. This structural conservatism improves flexibility to manage long R&D cycles and pursue non-debt funding (equity, partnerships) without heavy interest burdens.
Negative Factors
Minimal-to-zero revenue
Absent meaningful revenue, the company cannot self-fund R&D or operations and must rely on external capital or deals. Over a 2–6 month horizon this structural lack of commercial cash flow maintains reliance on financing, reduces margin visibility, and makes long-term sustainability contingent on funding or clinical success.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage (debt-free recent years)
Reported zero debt in 2024–2025 reduces fixed financing obligations and lowers near-term bankruptcy risk for a development-stage biotech. This structural conservatism improves flexibility to manage long R&D cycles and pursue non-debt funding (equity, partnerships) without heavy interest burdens.
Read all positive factors
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.28B
Dividend YieldN/A
Average Volume (3M)719.68K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue GrowthN/A
EPS Growth14.26%
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-24.01
Shares Outstanding96,334,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Modalis Therapeutics Corporation Business Overview & Revenue Model
Company Description
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic ...
How the Company Makes Money
null...
Modalis Therapeutics Corporation Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 40.50M | 1.10M |
| Gross Profit | -583.00K | 0.00 | 0.00 | -731.00K | -83.17M | 1.10M |
| EBITDA | -2.33B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -1.56B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 3.42B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.26B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 0.00 | 0.00 | 0.00 | 412.50M | 0.00 | 0.00 |
| Total Liabilities | 228.82M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 3.19B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0.00 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0.00 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0.00 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Negative
56.00
Price Trends
54.32
Negative
56.69
Negative
64.97
Negative
Market Momentum
-6.89
Positive
27.83
Positive
9.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Negative. The current price of 56 is above the 20-day moving average (MA) of 46.85, above the 50-day MA of 54.32, and below the 200-day MA of 64.97, indicating a bearish trend. The MACD of -6.89 indicates Positive momentum. The RSI at 27.83 is Positive, neither overbought nor oversold. The STOCH value of 9.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4883.
Modalis Therapeutics Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥12.67B | 23.72 | ― | ― | 1.62% | -25.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥5.52B | 27.79 | ― | 3.21% | 1.60% | -32.76% | |
48 Neutral | ¥5.42B | -6.47 | ― | ― | 246.42% | 9.39% | |
42 Neutral | ¥3.28B | -1.66 | ― | ― | ― | 14.26% | |
42 Neutral | ¥6.28B | -6.93 | -90.96% | ― | 24.62% | 60.41% | |
41 Neutral | ¥5.34B | -0.80 | ― | ― | -39.73% | -9.00% |
* Healthcare Sector Average
JP:4883
Modalis Therapeutics Corporation
34.00
-58.00
-63.04%
JP:4597
Solasia Pharma KK
23.00
-7.00
-23.33%
JP:4539
Nippon Chemiphar Co., Ltd.
1,528.00
90.87
6.32%
JP:4574
Taiko Pharmaceutical Co., Ltd.
253.00
5.00
2.02%
JP:4582
Symbio Pharmaceuticals Limited
70.00
-104.00
-59.77%
JP:4892
Cyfuse Biomedical K.K.
537.00
-376.00
-41.18%
Modalis Therapeutics Corporation Corporate Events
Modalis Books ¥14 Million in FX Gains, Boosting Quarterly Results
May 13, 2026
Modalis Therapeutics Corporation reported non-operating income of 14 million yen in foreign exchange gains for the three months ended March 31, 2026, driven primarily by the revaluation of its foreign currency-denominated assets and liabilities am...
Modalis outlines conditions and limitations around its Q1 2026 disclosure
May 13, 2026
Modalis Therapeutics has released its business and financial report for the first quarter of 2026, providing an update on its operations and corporate status. The document is positioned as an informational, reference-only English translation of th...
Modalis Narrows Quarterly Loss but Keeps Outlook Uncertain Amid Zero Revenue
May 13, 2026
Modalis Therapeutics reported no operating revenue for the quarter ended March 31, 2026, and narrowed its loss attributable to owners of the parent to ¥323 million from ¥652 million a year earlier. Basic loss per share improved to ¥...
Modalis Sells Idle U.S. Equipment, Books Extraordinary Gain on Asset Transfer
Apr 27, 2026
Modalis Therapeutics’ U.S. subsidiary in Waltham, Mass., has decided to transfer machinery and equipment that have become idle following the completion of their intended roles in process development, as part of a broader effort to improve ma...
Modalis Sets Terms for 18th Stock Option Plan, Issuing 935,000 Potential Shares
Apr 14, 2026
Modalis Therapeutics has set the detailed terms for its 18th stock option program, confirming an exercise price of 6,100 yen per unit, equivalent to 61 yen per share, calculated as the higher of a 5% premium over the prior month’s average cl...
Modalis Therapeutics Issues 18th Series Stock Options to Align Incentives and Retain Talent
Mar 26, 2026
Modalis Therapeutics has approved the issuance of its 18th series of stock options, granting 9,450 share acquisition rights to 21 grantees, including three directors and employees of the company and its subsidiary. The options, issued free of char...
Modalis Outlines FY2025 Growth Plans in Confidential TSE-Mandated Update
Mar 25, 2026
Modalis Therapeutics Corporation released its FY2025 year-end business plan update, outlining matters related to its growth potential and operational outlook. The company emphasized that the materials are for informational purposes only, may chang...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.